Warning! GuruFocus detected
1 Severe warning sign
with ASND.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Ascendis Pharma AS
NAICS : 325411
SIC : 2833
ISIN : US04351P1012
Share Class Description:
ASND: ADRCompare
Compare
Traded in other countries / regions
ASND.USAASND.MexicoA1SN34.BrazilA71.Germany IPO Date
2015-01-28Description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.65 | |||||
| Equity-to-Asset | -0.09 | |||||
| Debt-to-Equity | -8.1 | |||||
| Debt-to-EBITDA | -3.47 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.84 | |||||
| Beneish M-Score | -1.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 245.1 | |||||
| 3-Year EBITDA Growth Rate | 11.3 | |||||
| 3-Year EPS without NRI Growth Rate | 10.7 | |||||
| 3-Year FCF Growth Rate | 15.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 64.45 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.35 | |||||
| 9-Day RSI | 42.22 | |||||
| 14-Day RSI | 47.93 | |||||
| 3-1 Month Momentum % | 8.21 | |||||
| 6-1 Month Momentum % | 7.79 | |||||
| 12-1 Month Momentum % | 1.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.17 | |||||
| Quick Ratio | 0.84 | |||||
| Cash Ratio | 0.62 | |||||
| Days Inventory | 2074.78 | |||||
| Days Sales Outstanding | 65.18 | |||||
| Days Payable | 761.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.7 | |||||
| Shareholder Yield % | -5.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.75 | |||||
| Operating Margin % | -78.05 | |||||
| Net Margin % | -105.46 | |||||
| FCF Margin % | -85.17 | |||||
| ROA % | -40.75 | |||||
| ROIC % | -33.16 | |||||
| 3-Year ROIIC % | 36.64 | |||||
| ROC (Joel Greenblatt) % | -217.39 | |||||
| ROCE % | -242.26 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.62 | |||||
| EV-to-EBIT | -34.22 | |||||
| EV-to-Forward-EBIT | -44.1 | |||||
| EV-to-EBITDA | -36.75 | |||||
| EV-to-Forward-EBITDA | -47.81 | |||||
| EV-to-Revenue | 24.38 | |||||
| EV-to-Forward-Revenue | 15.98 | |||||
| EV-to-FCF | -28.53 | |||||
| Price-to-GF-Value | 0.4 | |||||
| Price-to-Median-PS-Value | 0.1 | |||||
| Earnings Yield (Greenblatt) % | -2.92 | |||||
| FCF Yield % | -3.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ASND
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascendis Pharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 389.281 | ||
| EPS (TTM) ($) | -7.135 | ||
| Beta | 0.41 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 0.57 | ||
| Volatility % | 33.1 | ||
| 14-Day RSI | 47.93 | ||
| 14-Day ATR ($) | 6.776105 | ||
| 20-Day SMA ($) | 156.23975 | ||
| 12-1 Month Momentum % | 1.63 | ||
| 52-Week Range ($) | 111.09 - 169.37 | ||
| Shares Outstanding (Mil) | 60.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascendis Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascendis Pharma AS Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ascendis Pharma AS Frequently Asked Questions
What is Ascendis Pharma AS(ASND)'s stock price today?
The current price of ASND is $149.90. The 52 week high of ASND is $169.37 and 52 week low is $111.09.
When is next earnings date of Ascendis Pharma AS(ASND)?
The next earnings date of Ascendis Pharma AS(ASND) is 2025-05-02 Est..
Does Ascendis Pharma AS(ASND) pay dividends? If so, how much?
Ascendis Pharma AS(ASND) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers